CTRI/2013/04/003549进行中（未招募）3 期
Prospective, multi-centre, randomized, open-label, twoarm,parallel group, active-control, comparative clinicalstudy to evaluate efficacy, safety and pharmacokineticsof R-TPR-016/ Herceptin® when given intravenously inpatients with Metastatic HER2-Overexpressing BreastCancer
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •2. Histologically or cytologically confirmed adenocarcinoma of the breast with locally advanced or metastatic disease that is HER2 positive as confirmed by positive fluorescence in situ hybridization (FISH) or by immunohistochemistry 3+ score.
- •3. Patients who have received adjuvant therapy and/or completed no more than 1 regimen of chemotherapy for metastatic disease. Any previous chemotherapy exposure should have been completed >3 weeks before randomization into the present study.
- •4. Eastern Cooperative Oncology Group (ECOG) performance status <=2.
- •5. At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (specifically, ascites, pleural, or pericardial effusions,
- •osteoblastic bone metastases, or carcinomatous lymphangitis of the lung cannot be the only lesion)
- •6. Normal laboratory tests including ANC >=1.5x109/L, Platelets >=100x109/L, Hemoglobin >9.0 g/dL, Serum Creatinine <= 1.5 ULN and Total bilirubin <= 1.5 mg/dL.
- •7. Subjects with baseline cardiac ejection fraction >= 50% by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan.
- •8. Estimated life expectancy >6 months
- •9. Able to understand the study procedures, the risks involved, willing to provide written Informed Consent, and able to adhere to study schedules and requirements.
排除标准
- •1. Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease, wound healing disorders, ulcers or bone fractures)
- •2. Patients with history of radiation within 4 weeks before the first cycle of chemotherapy in the study or planning radiation during the first 3 cycles of the study.
- •3. Previous bone marrow or stem-cell transplantation
- •4. Diagnosis of concurrent second malignancy or leukemia, myeloid aplasia, aplastic anemia, sickle cell disease and/or lymphoma with marrow involvement and/or known
- •brain metastases
- •5. History of chemotherapy causing delayed myelosuppression (nitrosureas, mitomycin C, etc.)
- •6. History of trastuzumab administration <= 21 days prior to randomization.
- •7. Current clinical or radiographic evidence of central nervous system (CNS) metastases.
- •8. History of exposure to the following cumulative doses of anthracyclines: Doxorubicin or liposomal doxorubicin 500 mg/m2; Epirubicin 900 mg/m2; Mitoxantrone 120mg/m2 and idarubicin 90 mg/m2
- •9. Major surgical procedure or significant traumatic injury within approximately 28 days prior to randomization or anticipation of the need for major surgery during the course
- •of study treatment
- •10. History of intolerance (including Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab, murine proteins or paclitaxel
- •11. Serious inter-current chronic or acute illness such as pulmonary (asthma or COPD) or cardiac (NYHA class III or IV) or hepatic disease or other illness considered by the
- •Principal Investigator to constitute an unwarranted high risk for investigational drug treatment
- •12. Severe dyspnoea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy.
- •13. Cardiac disease that would preclude the use of doxorubicin, docetaxel and trastuzumab:
- •o Any documented myocardial Infarction
- •o Angina pectoris that requires the use of anti-angina medication
- •o Any history of documented congestive heart failure
- •o Grade 3 or Grade 4 cardiac arrhythmia
- •o Clinically significant valvular heart disease
- •o Patients with cardiomegaly on chest x-ray or ventricular hypertrophy on ECG, unless they demonstrate by MUGA scan within the past 3 months that the LVEF is >= the lower limit of normal for the radiology facility;
- •o LVEF below 50% within approximately 28 days prior to randomization
- •o Patients with poorly controlled hypertension i.e. diastolic greater than 100 mm/Hg. (Patients who are well controlled on medication are eligible for entry)
- •o Patients who currently receive medications (digitalis, beta-blockers, calcium channel blockers, etc) that alter cardiac conduction, if these medications are administered for cardiac arrhythmia, angina or congestive heart failure. If these medications are administered for other reasons (e.g., hypertension), the patient will be eligible.
- •14. Pre-existing grade 2 or greater motor or sensory neuropathy.
- •15. Women who are pregnant or breast-feeding or women of child bearing potential who are not using effective contraception during participation in the study and do not
- •agree to do so for at least 28 days after final dose of investigational product.
- •16. Serious underlying medical condition which could impair the ability of patient to participate in the trial (e.g. acti
研究者
相似试验
进行中（未招募）
3 期
A clinical trial to study the effects of two drugs, R-TPR-026 andAranesp® in patients for correction of anemia due to Chronic Kidney DiseaseCTRI/2013/09/004005Reliance Life sciences Pvt Ltd104
进行中（未招募）
3 期
A clinical trial to study the effects of two drugs, R-TPR-023 and Avastinâ?¢ in patients with Metastatic colorectal cancerCTRI/2013/05/003699Reliance Life sciences Pvt Ltd105
进行中（未招募）
1 期
Prospective, multicenter, randomized, open-label, parallel-group controlled phase 3 study of tacrolimus minimization in kidney transplant recipients selected according to the AGORA algorithm for their low immunological risk and medium-term graft failurekidney transplantationCTIS2022-502624-44-00Centre Hospitalier Universitaire De Nantes332
终止
2 期
Stroke Self-Management Rehabilitation Trial (SMART)self-managementrehabilitationStroke - IschaemicStroke - HaemorrhagicstrokeACTRN12612001287820ational Institute for Stroke & Applied Neurosciences, AUT University700
进行中（未招募）
1 期
Multicentre, prospective, randomized, open-label, controlled study in de novo kidney transplant recipients to evaluate the impact of cyclosporine or steroid withdrawal at 3 months on graft function, patient and graft survival, and cardiovascular surrogate markers during the first five years after transplantation. - CistcertPreservation of renal function after kidney transplantation in a 5-year, multicentre, prospective, randomized, open-label, controlled studyPatients will be randomized within 24 hours prior to transplantation.?Group 1: Simulect + Neoral + Myfortic + steroid stop at 3 months?Group 2: Simulect + Neoral (decrease dose in one week at mo 3 and replace by Certican) + Myfortic + steroid maintenance.EUCTR2007-005844-26-BEAntwerp University Hospital